Inhibikase Therapeutics (IKT) P/E (2020 - 2026)
Inhibikase Therapeutics (IKT) P/E from Dec 31, 2020 to Jul 21, 2026. The TTM Inhibikase Therapeutics (IKT) P/E is -4.34. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Inhibikase Therapeutics (IKT)
| Year | P/E | Change |
|---|---|---|
| 2026 | -4.34 | +21.49% |
| 2025 | -3.58 | -40.78% |
| 2024 | -6.04 | +203.86% |
| 2023 | -1.99 | -50.57% |
| 2022 | -4.02 | -66.02% |
| 2021 | -11.83 | -96.56% |
| 2020 | -343.89 | N/A |
Comparison Inhibikase Therapeutics (IKT) P/E with competitors
Inhibikase Therapeutics (IKT) P/E is -4.34.